Constipation, a common symptom in clinical practice, affects up to 20% of the world's population. It has a significant impact on patient's quality of life and healthcare resources. With advancements in medical knowledge and technology, there is a need to revisit our approach to constipation.
Traditionally, constipation is diagnosed based on clinical symptoms and Rome IV criteria. However, this approach often overlooks underlying pathophysiology. Modern techniques such as high-resolution anorectal manometry and transluminal impedance measurement can provide detailed information about the functional status of the colon and rectum, aiding in accurate diagnosis.
Treatment should be tailored to the individual patient's needs. Lifestyle modifications and over-the-counter laxatives are the first-line treatments. However, for patients with refractory symptoms, newer pharmacological agents like linaclotide and plecanatide, which increase intestinal fluid secretion and transit, can be beneficial.
Biofeedback therapy, which uses sensors to make patients aware of physiological functions, has proven effective in treating pelvic floor dyssynergia, a common cause of constipation. This non-invasive therapy can be a game-changer for patients who do not respond to traditional treatments.
For patients with severe, refractory constipation, surgical interventions such as sacral nerve stimulation and subtotal colectomy are being increasingly considered. These procedures, although invasive, can significantly improve symptoms and quality of life in select patients.
In conclusion, the approach to constipation has evolved significantly over the years. Modern diagnostic tools allow for a more precise understanding of the pathophysiology, leading to personalized treatment plans. Innovative therapies and surgical approaches hold promise for patients with refractory symptoms. As healthcare professionals, we must stay abreast of these advancements to provide optimal patient care.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation